A Phase 1 interventional study of VH3810109 and rHuPH20 in HIV Infections, sponsored by ViiV Healthcare. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-09-19.
Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 266 studies in HIV Infections by GlaxoSmithKline — 15 open to participants now, 27 under way, 8 of them phase 3. HIV Infections · GlaxoSmithKline.
Among the 266 studies in HIV Infections by GlaxoSmithKline, this one is the 169th largest by enrollment of the 210 interventional ones that give a count, is one of 6 that started in 2022, is one of 83 in phase 1, and was the 226th registered.
4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.
Browse HIV Infections studies →15 of the 266 studies in HIV Infections by GlaxoSmithKline are open now, in 12 countries. Recruiting first, the newest first:
ViiV Healthcare · Sites in United States
Ages 18–55 · Healthy volunteers
ViiV Healthcare · Sites in Romania, South Africa, Uganda
ViiV Healthcare · Sites in Netherlands
Ages 18–55 · Healthy volunteers
ViiV Healthcare · Sites in United States
Ages 18–55 · Healthy volunteers
ViiV Healthcare · Sites in South Africa
Ages up to 10 days · Healthy volunteers
By country, each count listing its studies:
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
266 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 85 · Phase 2 53 · Phase 3 68 · Phase 4 18
First in 1994; this study’s year is marked. 6 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 24 is below the median of 80 across 3,492 interventional studies indexed under HIV Infections.
Median enrollment 82 across the 210 interventional studies, 328 across the 14 observational. Of the 230 that completed or were terminated, 95 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under ViiV Healthcare, one of the names counted as GlaxoSmithKline. Under that name alone:
ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.
6 of the studies in HIV Infections by GlaxoSmithKline that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07053384ViiV HealthcareA Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV | 2027-01-22 |
| NCT07934719ViiV HealthcareMass Balance and Absolute Bioavailability of [14C]-VH4011499 | 2027-02-18 |
| NCT06786520ViiV HealthcareA Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Cabotegravir Ultra Long-acting (CAB ULA) Following Switch From Cabotegravir Long-acting (CAB LA) in Healthy Adults | 2027-03-08 |
| NCT07939594ViiV HealthcareAn Evaluation of the Potential for VH4011499 Drug-drug-interactions | 2027-03-12 |
| NCT07525544ViiV HealthcareA Study to Investigate the Safety and PK of VH4770359 in Healthy Participants | 2027-05-05 |
Add all 6 to your calendar (.ics) → With an account.
Among the 266 studies in HIV Infections by GlaxoSmithKline, from their registry updates:
This tab as a report to print or save as PDF → With an account.
An open-label, two part study to assess the safety, tolerability, and PK of VH3810109 in healthy adult participants. Participants will receive a single SC or IV dose of VH3810109 co-administered with rHuPH20 and will be followed up for 24 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants who are female at birth are eligible to participate if at least one of the following conditions applies:
Not pregnant or breastfeeding and at least one of the following conditions applies:
Is not a participant of (POCBP) or Is a POCBP and agree to use an acceptable contraceptive method as described in Section 10.4 from 3 weeks prior to the start of this study and during the study. The investigator should evaluate the effectiveness of the contraceptive method in relationship to the first dose of study intervention.
A POCBP must have a negative highly sensitive serum pregnancy test on Day -1, prior to the first dose of study intervention All participants in the study should be counseled on safer sexual practices including the use and benefit/risk of effective barrier methods (e.g., male condom).
The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a POCBP with an early undetected pregnancy.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this group received a single subcutaneous (SC) dose of VH3810109 20 mg/kg co-administered with rHuPH20 at Day 1 and were followed up to 24 weeks.
Biological: VH3810109 · Biological: rHuPH20
Participants in this group received a single intravenous (IV) dose of VH3810109 60 mg/kg at Day 1 and were followed up to 24 weeks.
Biological: VH3810109
Participants in this group received a single subcutaneous (SC) dose of VH3810109 3000 mg co-administered with rHuPH20 at Day 1 and were followed up to 24 weeks.
Biological: VH3810109 · Biological: rHuPH20
Number of Participants With Grade 2 or Higher (>=) Adverse Events (AEs) Following SC Administration of VH3810109 (Part 1 and Part 3)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. The Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric AE was used for all AE severity grading, where Grade 1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening. This outcome measure is presenting only data for Grade 2 or more of severity.
Time frame: Up to Week 24
Number of Participants With Serious Adverse Events (SAEs) Following SC Administration of VH3810109 (Part 1 and Part 3)
An SAE is defined as any untoward medical occurrence that; results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect or other situations as judged by physician.
Time frame: Up to Week 24
Number of Participants With Injection Site Reactions (ISRs) Following VH3810109 SC Administration (Part 1 and 3)
ISRs were recorded via ISR diaries and managed through investigator assessment. The participants who experienced any injection site reaction were reported.
Time frame: Up to 7 days post-dose
Number of Participants With Grade 2 to 4 Elevated Alanin Aminotransferase/Aspartate Aminotransferase (ALT/AST) Values Following VH3810109 SC Administration (Part 1 and 3)
Liver chemistry stopping and increased monitoring criteria is analyzed using DAIDS AE Grading Table, where Grade 2 (moderate): causing greater than minimal interference with usual social and functional activities, Grade 3 (severe): causing inability to perform usual social and functional activities, Grade 4 (Potentially life threatening): causing inability to perform basic self-care functions or hospitalization indicated.
Time frame: Up to Week 24
Number of Participants With >= Grade 2 AEs Following IV Administration of VH3810109 (Part 2)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. The Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric AE was used for all AE severity grading, where Grade 1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening. This outcome measure is presenting only data for Grade 2 or more of severity.
Time frame: Up to Week 24
Number of Participants With SAEs Following IV Administration of VH3810109 (Part 2)
An SAE is defined as any untoward medical occurrence that; results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect or other situations as judged by physician.
Time frame: Up to Week 24
Number of Participants With Grade 2 to 4 Elevated ALT/AST Values Following VH3810109 IV Administration (Part 2)
Liver chemistry stopping and increased monitoring criteria is analyzed using DAIDS AE Grading Table, where Grade 2 (moderate): causing greater than minimal interference with usual social and functional activities, Grade 3 (severe): causing inability to perform usual social and functional activities, Grade 4 (Potentially life threatening): causing inability to perform basic self-care functions or hospitalization indicated.
Time frame: Up to Week 24
Area Under the Plasma Concentration-time Curve (AUC) From Time Zero Extrapolated to Infinity (AUC[0-inf]) of VH3810109
Blood samples were collected as assessed by protocol, at specific time points for pharmacokinetic (PK) analysis of VH3810109.
Time frame: Up to Week 24
AUC From Time Zero to Time t (AUC[0-t]) of VH3810109
Blood samples were collected as assessed by protocol, at specific time points for PK analysis of VH3810109.
Time frame: Up to Week 24
Maximum Observed Concentration (Cmax) of VH3810109
Blood samples were collected as assessed by protocol, at specific time points for PK analysis of VH3810109.
Time frame: Up to Week 24
Time of Maximum Observed Concentration (Tmax) of VH3810109
Blood samples were collected as assessed by protocol, at specific time points for PK analysis of VH3810109.
Time frame: Up to Week 24
Apparent Terminal Phase Half-life (t1/2) of VH3810109
Blood samples were collected as assessed by protocol, at specific time points for PK analysis of VH3810109.
Time frame: Up to Week 24
Score Recorded for "Acceptance of ISRs", Using Perception of Injection (PIN) Questionnaire (Part 1 and 3)
The PIN questionnaire measure contains 21 items: pain at injection site, local site reactions, impact on functioning and willingness to pursue injectable treatment outside clinical trial. Scores range from 1 to 5; questions are phrased to ensure that 1: most favorable perception of vaccination, and 5: most unfavorable. Score of a dimension is calculated as mean of all items with dimension. Higher scores represent worse perception of injection.
Time frame: At Day 2 and Day 7
Number of Participants Reporting Pain, Using Perception of Injection (PIN) Questionnaire (Part 1 and 3)
The PIN questionnaire measure contains 21 items: pain at injection site, local site reactions, impact on functioning and willingness to pursue injectable treatment outside clinical trial. Scores range from 1 to 5; the scores are defined as following: 1=not at all bothered, 2=a little bothered, 3=moderately bothered, 4=very bothered, 5=extremely bothered; questions are phrased to ensure that 1: most favorable perception of vaccination, and 5: most unfavorable. Score of a dimension is calculated as mean of all items with dimension. Higher scores represent worse perception of injection.
Time frame: At Day 2 and Day 7
Number of Participants Reporting Being Bothered or Affected by the Pain and Local Reactions Based on the PIN Questionaire (Part 1 and 3)
The PIN questionnaire measure contains 21 items: pain at injection site, local site reactions, impact on functioning and willingness to pursue injectable treatment outside clinical trial. Scores range from 1 to 5; the scores are defind as following: 1=totaly acceptable, 2=very acceptable, 3=moderately acceptable, 4=a little acceptable, 5=not at all acceptable; questions are phrased to ensure that 1: most favorable perception of vaccination, and 5: most unfavorable. Score of a dimension is calculated as mean of all items with dimension. Higher scores represent worse perception of injection.
Time frame: At Day 2 and Day 7
Score Reported for Post-injection Pain Assessment Using Numeric Rating Scale (NRS) Following VH3810109 SC Administration (Part 1 and 3)
Post-injection assessment of pain was measured based on NRS which is a 11-point numerical rating scale ranging from 0 (no pain) to 10 (worst possible pain).
Time frame: At Day 1, Day 2 and Day 7
Scores Reported for Post-injection Pain Assessment Using Numeric Rating Scale (NRS) Following VH3810109 IV Administration (Part 2)
Post-injection assessment of pain was measured based on NRS which is a 11-point numerical rating scale ranging from 0 (no pain) to 10 (worst possible pain).
Time frame: At Day 1, Day 2 and Day 7
Number of ISRs Events Overall and by Grade (Part 1 and 3)
ISRs were recorded via ISR diaries and managed through investigator assessment. Severity of injection site reactions was analyzed using DAIDS AE Grading Table. The severity was categorized into grades as following: Grade 1 (mild): causing no or minimal interference with usual social and functional activities, Grade 2 (moderate): causing greater than minimal interference with usual social and functional activities, Grade 3 (severe): causing inability to perform usual social and functional activities, Grade 4 (Potentially life threatening): causing inability to perform basic self-care functions or hospitalization indicated, Grade 5 (death). Higher grade indicates more severe condition.
Time frame: Up to day 14
The Overall Duration of ISRs, Expressed in Days
ISRs will be recorded via ISR diaries and managed through investigator assessment.
Time frame: From Day 1 up to Day 14
Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils
Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of VH3810109.
Time frame: From Baseline (Day -1) up to Week 24
Change From Baseline in Hematocrit
Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of VH3810109.
Time frame: From Baseline (Day -1) up to Week 24
Change From Baseline in Hemoglobin, Albumin and Total Protein
Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of VH3810109.
Time frame: From Baseline (Day -1) up to Week 24
Change From Baseline in Red Blood Cell Count (RBC)
Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of VH3810109.
Time frame: From Baseline (Day -1) up to Week 24
Change From Baseline in Mean Corpuscle Volume (MCV)
Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of VH3810109.
Time frame: From Baseline (Day -1) up to Week 24
Change From Baseline in Mean Corpuscle Hemoglobin (MCH)
Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of VH3810109.
Time frame: From Baseline (Day -1) up to Week 24
Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin
Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of VH3810109.
Time frame: From Baseline (Day -1) up to Week 24
Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide
Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of VH3810109.
Time frame: From Baseline (Day -1) up to Week 24
Change From Baseline in ALT, AST and Alkaline Phosphatase (ALP)
Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of VH3810109.
Time frame: From Baseline (Day -1) up to Week 24
Number of Participants With Worst Case Urinalysis at Post-baseline Compared With Baseline
Urine samples were collected as assessed by protocol, at specific time points for laboratory analysis of VH3810109. At baseline and post-baseline, worst case urinalysis data was determined by comparing the resulted values of the urinalysis for each participant to the normal rage. This endpoint evaluates the changes from baseline for the worst case urinalysis.
Time frame: Day 14 compared with baseline (Day -1)
Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)
ECG values were collected as assessed by protocol, at the indicated time points.
Time frame: From Baseline (Day -1) up to Week 24
Change From Baseline in Temperature
Temperature was measured at the indicated time points, in a supine position after the participant has been at rest for at least 5 minutes in a quiet setting without distractions.
Time frame: From Baseline (Day -1) up to Week 24
Change From Baseline in Pulse Rate
Pulse rate was measured at the indicated time points, in a supine position after the participant has been at rest for at least 5 minutes in a quiet setting without distractions.
Time frame: From Baseline (Day -1) up to Week 24
Change From Baseline in Respiratory Rate
Respiratory rate was measured at the indicated time points, in a supine position after the participant has been at rest for at least 5 minutes in a quiet setting without distractions.
Time frame: From Baseline (Day -1) up to Week 24
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
Blood pressure was measured at the indicated time points, in a supine position after the participant has been at rest for at least 5 minutes in a quiet setting without distractions.
Time frame: From Baseline (Day -1) up to Week 24
| Milestone | Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC] | Part 2 Group: VH3810109 60 mg/kg [IV] | Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC] |
|---|---|---|---|
| Started | 8 | 8 | 8 |
| Completed | 8 | 8 | 7 |
| Not completed | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. The Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric AE was used for all AE severity grading, where Grade 1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening. This outcome measure is presenting only data for Grade 2 or more of severity.
| Participants | Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC] | Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC] |
|---|---|---|
| Number of Participants With Grade 2 or Higher (>=) Adverse Events (AEs) Following SC Administration of VH3810109 (Part 1 and Part 3) | 7 | 8 |
An SAE is defined as any untoward medical occurrence that; results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect or other situations as judged by physician.
| Participants | Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC] | Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC] |
|---|---|---|
| Number of Participants With Serious Adverse Events (SAEs) Following SC Administration of VH3810109 (Part 1 and Part 3) | 0 | 0 |
ISRs were recorded via ISR diaries and managed through investigator assessment. The participants who experienced any injection site reaction were reported.
| Participants | Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC] | Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC] |
|---|---|---|
| Number of Participants With Injection Site Reactions (ISRs) Following VH3810109 SC Administration (Part 1 and 3) | 7 | 8 |
Liver chemistry stopping and increased monitoring criteria is analyzed using DAIDS AE Grading Table, where Grade 2 (moderate): causing greater than minimal interference with usual social and functional activities, Grade 3 (severe): causing inability to perform usual social and functional activities, Grade 4 (Potentially life threatening): causing inability to perform basic self-care functions or hospitalization indicated.
| Participants | Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC] | Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC] |
|---|---|---|
| ALT, Grade 2 | 0 | 0 |
| ALT, Grade 3 | 0 | 0 |
| ALT, Grade 4 | 0 | 0 |
| AST, Grade 2 | 0 | 0 |
| AST, Grade 3 | 0 | 0 |
| AST, Grade 4 | 0 | 0 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. The Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric AE was used for all AE severity grading, where Grade 1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening. This outcome measure is presenting only data for Grade 2 or more of severity.
| Participants | Part 2 Group: VH3810109 60 mg/kg [IV] |
|---|---|
| Number of Participants With >= Grade 2 AEs Following IV Administration of VH3810109 (Part 2) | 0 |
An SAE is defined as any untoward medical occurrence that; results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect or other situations as judged by physician.
| Participants | Part 2 Group: VH3810109 60 mg/kg [IV] |
|---|---|
| Number of Participants With SAEs Following IV Administration of VH3810109 (Part 2) | 0 |
Liver chemistry stopping and increased monitoring criteria is analyzed using DAIDS AE Grading Table, where Grade 2 (moderate): causing greater than minimal interference with usual social and functional activities, Grade 3 (severe): causing inability to perform usual social and functional activities, Grade 4 (Potentially life threatening): causing inability to perform basic self-care functions or hospitalization indicated.
| Participants | Part 2 Group: VH3810109 60 mg/kg [IV] |
|---|---|
| ALT, Grade 2 | 0 |
| ALT, Grade 3 | 0 |
| ALT, Grade 4 | 0 |
| AST, Grade 2 | 0 |
| AST, Grade 3 | 0 |
| AST, Grade 4 | 0 |
Blood samples were collected as assessed by protocol, at specific time points for pharmacokinetic (PK) analysis of VH3810109.
| Day*microgram/mililitre (day*μg/mL) | Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC] | Part 2 Group: VH3810109 60 mg/kg [IV] | Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC] |
|---|---|---|---|
| Area Under the Plasma Concentration-time Curve (AUC) From Time Zero Extrapolated to Infinity (AUC[0-inf]) of VH3810109 | 7587 (4789 to 10380) | 31560 (27620 to 35490) | 12840 (8883 to 16800) |
Blood samples were collected as assessed by protocol, at specific time points for PK analysis of VH3810109.
| day*μg/mL | Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC] | Part 2 Group: VH3810109 60 mg/kg [IV] | Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC] |
|---|---|---|---|
| AUC From Time Zero to Time t (AUC[0-t]) of VH3810109 | 6996 (4512 to 9479) | 29160 (25550 to 32770) | 11590 (7819 to 15360) |
Blood samples were collected as assessed by protocol, at specific time points for PK analysis of VH3810109.
| μg/mL | Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC] | Part 2 Group: VH3810109 60 mg/kg [IV] | Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC] |
|---|---|---|---|
| Maximum Observed Concentration (Cmax) of VH3810109 | 148.2 (117.3 to 179.1) | 1864 (1620 to 2107) | 321.1 (201.6 to 440.6) |
Blood samples were collected as assessed by protocol, at specific time points for PK analysis of VH3810109.
| Days | Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC] | Part 2 Group: VH3810109 60 mg/kg [IV] | Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC] |
|---|---|---|---|
| Time of Maximum Observed Concentration (Tmax) of VH3810109 | 4.503 (1.472 to 7.535) | 0.046 (0.045 to 0.047) | 2.882 (2.586 to 3.178) |
Blood samples were collected as assessed by protocol, at specific time points for PK analysis of VH3810109.
| Days | Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC] | Part 2 Group: VH3810109 60 mg/kg [IV] | Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC] |
|---|---|---|---|
| Apparent Terminal Phase Half-life (t1/2) of VH3810109 | 38.17 (23.41 to 52.93) | 46.97 (40.86 to 53.09) | 44.95 (34.14 to 55.76) |
The PIN questionnaire measure contains 21 items: pain at injection site, local site reactions, impact on functioning and willingness to pursue injectable treatment outside clinical trial. Scores range from 1 to 5; questions are phrased to ensure that 1: most favorable perception of vaccination, and 5: most unfavorable. Score of a dimension is calculated as mean of all items with dimension. Higher scores represent worse perception of injection.
| Scores on a scale | Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC] | Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC] |
|---|---|---|
| Acceptance of ISRs, Day 2 | 1.44 ± 1.050 | 1.44 ± 0.496 |
| Acceptance of ISRs, Day 7 | 1.44 ± 0.729 | 1.50 ± 0.802 |
The PIN questionnaire measure contains 21 items: pain at injection site, local site reactions, impact on functioning and willingness to pursue injectable treatment outside clinical trial. Scores range from 1 to 5; the scores are defined as following: 1=not at all bothered, 2=a little bothered, 3=moderately bothered, 4=very bothered, 5=extremely bothered; questions are phrased to ensure that 1: most favorable perception of vaccination, and 5: most unfavorable. Score of a dimension is calculated as mean of all items with dimension. Higher scores represent worse perception of injection.
| Participants | Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC] | Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC] |
|---|---|---|
| Not at all bothered by pain, Day 2 | 6 | 6 |
| A little bothered by pain, Day 2 | 2 | 2 |
| Moderately bothered by pain, Day 2 | 0 | 0 |
| Very bothered by pain, Day 2 | 0 | 0 |
| Extremely bothered by pain, Day 2 | 0 | 0 |
| Not at all bothered by pain, Day 7 | 5 | 5 |
| A little bothered by pain, Day 7 | 3 | 3 |
| Moderately bothered by pain, Day 7 | 0 | 0 |
| Very bothered by pain, Day 7 | 0 | 0 |
| Extremely bothered by pain, Day 7 | 0 | 0 |
The PIN questionnaire measure contains 21 items: pain at injection site, local site reactions, impact on functioning and willingness to pursue injectable treatment outside clinical trial. Scores range from 1 to 5; the scores are defind as following: 1=totaly acceptable, 2=very acceptable, 3=moderately acceptable, 4=a little acceptable, 5=not at all acceptable; questions are phrased to ensure that 1: most favorable perception of vaccination, and 5: most unfavorable. Score of a dimension is calculated as mean of all items with dimension. Higher scores represent worse perception of injection.
| Participants | Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC] | Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC] |
|---|---|---|
| Totally acceptable local reactions, Day 2 | 7 | 6 |
| Very acceptable local reactions, Day 2 | 0 | 1 |
| Moderately acceptable local reactions, Day 2 | 0 | 1 |
| A little acceptable local reactions, Day 2 | 1 | 0 |
| Not at all acceptable local reactions, Day 2 | 0 | 0 |
| Totally acceptable local reactions, Day 7 | 5 | 6 |
| Very acceptable local reactions, Day 7 | 2 | 1 |
| Moderately acceptable local reactions, Day 7 | 1 | 1 |
| A little acceptable local reactions, Day 7 | 0 | 0 |
| Not at all acceptable local reactions, Day 7 | 0 | 0 |
| Totally acceptable pain, Day 2 | 6 | 4 |
| Very acceptable pain, Day 2 | 1 | 4 |
| Moderately acceptable pain, Day 2 | 0 | 0 |
| A little acceptable pain, Day 2 | 1 | 0 |
| Not at all acceptable pain, Day 2 | 0 | 0 |
| Totally acceptable pain, Day 7 | 6 | 5 |
| Very acceptable pain, Day 7 | 1 | 1 |
| Moderately acceptable pain, Day 7 | 1 | 2 |
| A little acceptable pain, Day 7 | 0 | 0 |
| Not at all acceptable pain, Day 7 | 0 | 0 |
Post-injection assessment of pain was measured based on NRS which is a 11-point numerical rating scale ranging from 0 (no pain) to 10 (worst possible pain).
| Scores on a scale | Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC] | Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC] |
|---|---|---|
| Day 1 | 3.63 ± 2.326 | 2.75 ± 2.550 |
| Day 2 | 3.63 ± 2.615 | 0.63 ± 0.744 |
| Day 7 | 3.63 ± 2.925 | 0.38 ± 0.744 |
Post-injection assessment of pain was measured based on NRS which is a 11-point numerical rating scale ranging from 0 (no pain) to 10 (worst possible pain).
| Scores on a scale | Part 2 Group: VH3810109 60 mg/kg [IV] |
|---|---|
| Day 1 | 0.50 ± 1.069 |
| Day 2 | 0.88 ± 1.642 |
| Day 7 | 0.50 ± 1.414 |
ISRs were recorded via ISR diaries and managed through investigator assessment. Severity of injection site reactions was analyzed using DAIDS AE Grading Table. The severity was categorized into grades as following: Grade 1 (mild): causing no or minimal interference with usual social and functional activities, Grade 2 (moderate): causing greater than minimal interference with usual social and functional activities, Grade 3 (severe): causing inability to perform usual social and functional activities, Grade 4 (Potentially life threatening): causing inability to perform basic self-care functions or hospitalization indicated, Grade 5 (death). Higher grade indicates more severe condition.
| Number of events | Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC] | Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC] |
|---|---|---|
| Overall ISRs | 14 | 18 |
| Grade 1 ISRs | 2 | 6 |
| Grade 2 ISRs | 5 | 2 |
| Grade 3 ISRs | 7 | 10 |
| Grade 4 ISRs | 0 | 0 |
| Grade 5 ISRs | 0 | 0 |
ISRs will be recorded via ISR diaries and managed through investigator assessment.
| Days | Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC] | Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC] |
|---|---|---|
| The Overall Duration of ISRs, Expressed in Days | 2.9 ± 1.35 | 4.6 ± 6.29 |
Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of VH3810109.
| 10^9 cells/L | Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC] | Part 2 Group: VH3810109 60 mg/kg [IV] | Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC] |
|---|---|---|---|
| Basophils, at Baseline | 0.033 ± 0.0139 | 0.035 ± 0.0207 | 0.044 ± 0.0106 |
| Basophils, at Day 2 | -0.004 ± 0.0092 | 0.000 ± 0.0151 | -0.009 ± 0.0083 |
| Basophils, at Day 3 | — | 0.005 ± 0.0152 | -0.009 ± 0.0113 |
| Basophils, at Day 4 | — | 0.012 ± 0.0172 | -0.001 ± 0.0181 |
| Basophils, at Day 7 | 0.008 ± 0.0128 | 0.003 ± 0.0128 | -0.005 ± 0.0107 |
| Basophils, at Day 8 | — | 0.002 ± 0.0098 | — |
| Basophils, at Day 10 | — | 0.000 ± 0.0283 | — |
| Basophils, at Day 14 | 0.001 ± 0.0064 | 0.008 ± 0.0139 | 0.003 ± 0.0149 |
| Basophils, at Week 4 | 0.003 ± 0.0139 | 0.004 ± 0.0141 | 0.000 ± 0.0185 |
| Basophils, at Week 16 | -0.001 ± 0.0083 | 0.004 ± 0.0192 | -0.001 ± 0.0121 |
| Basophils, at Week 24 | 0.000 ± 0.0151 | 0.001 ± 0.0259 | -0.013 ± 0.0160 |
| Eosinophils, at Baseline | 0.121 ± 0.0957 | 0.098 ± 0.0333 | 0.145 ± 0.1370 |
| Eosinophils, at Day 2 | 0.018 ± 0.0851 | 0.010 ± 0.0151 | 0.016 ± 0.0385 |
| Eosinophils, at Day 3 | — | 0.017 ± 0.0121 | 0.010 ± 0.0513 |
| Eosinophils, at Day 4 | — | 0.022 ± 0.0194 | 0.010 ± 0.0431 |
| Eosinophils, at Day 7 | 0.016 ± 0.0964 | 0.000 ± 0.0293 | 0.016 ± 0.0619 |
| Eosinophils, at Day 8 | — | 0.003 ± 0.0320 | — |
| Eosinophils, at Day 10 | — | -0.010 ± 0.0424 | — |
| Eosinophils, at Day 14 | 0.059 ± 0.0718 | 0.011 ± 0.0624 | 0.025 ± 0.0444 |
| Eosinophils, at Week 4 | 0.045 ± 0.0644 | 0.001 ± 0.0290 | -0.004 ± 0.0403 |
| Eosinophils, at Week 16 | 0.059 ± 0.1667 | 0.053 ± 0.1269 | 0.013 ± 0.0605 |
| Eosinophils, at Week 24 | 0.001 ± 0.1063 | 0.094 ± 0.1445 | -0.001 ± 0.0527 |
| WBC, at Baseline | 5.13 ± 1.161 | 6.31 ± 1.365 | 6.50 ± 2.036 |
| WBC, at Day 2 | 0.43 ± 0.696 | -0.31 ± 1.253 | -0.36 ± 0.980 |
| WBC, at Day 3 | — | 0.13 ± 1.113 | -0.41 ± 1.089 |
| WBC, at Day 4 | — | 0.32 ± 1.386 | -0.49 ± 1.360 |
| WBC, at Day 7 | 0.11 ± 0.872 | -0.04 ± 1.171 | -0.25 ± 2.165 |
| WBC, at Day 8 | — | -0.05 ± 0.997 | — |
| WBC, at Day 10 | — | -0.85 ± 0.071 | — |
| WBC, at Day 14 | -0.26 ± 0.809 | -0.38 ± 0.791 | -0.25 ± 0.994 |
| WBC, at Week 4 | -0.03 ± 1.261 | -0.40 ± 0.857 | -0.48 ± 1.340 |
| WBC, at Week 16 | 0.01 ± 0.892 | -0.63 ± 1.073 | -0.64 ± 1.162 |
| WBC, at Week 24 | -0.46 ± 0.883 | 0.40 ± 2.438 | -0.51 ± 0.540 |
| Lymphocytes, at Baseline | 1.368 ± 0.2680 | 2.214 ± 0.5545 | 2.086 ± 0.4824 |
| Lymphocytes, at Day 2 | 0.006 ± 0.1908 | -0.484 ± 0.3503 | -0.094 ± 0.2147 |
| Lymphocytes, at Day 3 | — | -0.175 ± 0.3459 | -0.135 ± 0.2727 |
| Lymphocytes, at Day 4 | — | -0.065 ± 0.3551 | -0.106 ± 0.3847 |
| Lymphocytes, at Day 7 | -0.043 ± 0.1763 | -0.211 ± 0.3189 | -0.175 ± 0.3166 |
| Lymphocytes, at Day 8 | — | -0.193 ± 0.3462 | — |
| Lymphocytes, at Day 10 | — | -0.475 ± 0.0778 | — |
| Lymphocytes, at Day 14 | -0.019 ± 0.1664 | -0.386 ± 0.3366 | -0.161 ± 0.3561 |
| Lymphocytes, at Week 4 | 0.063 ± 0.1943 | -0.314 ± 0.2911 | -0.226 ± 0.2908 |
| Lymphocytes, at Week 16 | 0.100 ± 0.2441 | -0.190 ± 0.2478 | -0.191 ± 0.3559 |
| Lymphocytes, at Week 24 | 0.058 ± 0.3377 | -0.380 ± 0.3497 | -0.339 ± 0.4461 |
| Monocytes, at Baseline | 0.396 ± 0.1556 | 0.461 ± 0.1038 | 0.485 ± 0.1488 |
| Monocytes, at Day 2 | 0.091 ± 0.1037 | -0.048 ± 0.1159 | -0.008 ± 0.0587 |
| Monocytes, at Day 3 | — | 0.040 ± 0.0639 | -0.013 ± 0.0886 |
| Monocytes, at Day 4 | — | 0.080 ± 0.0957 | -0.006 ± 0.1034 |
| Monocytes, at Day 7 | 0.049 ± 0.1185 | -0.021 ± 0.1572 | -0.013 ± 0.1413 |
| Monocytes, at Day 8 | — | 0.008 ± 0.1019 | — |
| Monocytes, at Day 10 | — | -0.110 ± 0.1131 | — |
| Monocytes, at Day 14 | 0.034 ± 0.1347 | -0.078 ± 0.1237 | -0.015 ± 0.1319 |
| Monocytes, at Week 4 | 0.036 ± 0.1061 | -0.045 ± 0.1146 | -0.034 ± 0.1010 |
| Monocytes, at Week 16 | 0.023 ± 0.0630 | -0.029 ± 0.1221 | 0.001 ± 0.0724 |
| Monocytes, at Week 24 | -0.018 ± 0.1099 | 0.001 ± 0.1670 | -0.020 ± 0.0462 |
| Neutrophils, at Baseline | 3.218 ± 0.9157 | 3.499 ± 0.9783 | 3.756 ± 1.6757 |
| Neutrophils, at Day 2 | 0.315 ± 0.8333 | 0.214 ± 1.0869 | -0.263 ± 0.9093 |
| Neutrophils, at Day 3 | — | 0.238 ± 0.9621 | -0.291 ± 0.9503 |
| Neutrophils, at Day 4 | — | 0.262 ± 1.0730 | -0.398 ± 1.0114 |
| Neutrophils, at Day 7 | 0.066 ± 0.8177 | 0.210 ± 0.9063 | -0.079 ± 1.8480 |
| Neutrophils, at Day 8 | — | 0.160 ± 0.8802 | — |
| Neutrophils, at Day 10 | — | -0.270 ± 0.3111 | — |
| Neutrophils, at Day 14 | -0.340 ± 0.7531 | 0.096 ± 0.8912 | -0.116 ± 0.7571 |
| Neutrophils, at Week 4 | -0.160 ± 1.2887 | -0.036 ± 0.9269 | -0.233 ± 1.1531 |
| Neutrophils, at Week 16 | -0.178 ± 0.6481 | -0.468 ± 0.9437 | -0.500 ± 0.9401 |
| Neutrophils, at Week 24 | -0.535 ± 0.8511 | 0.691 ± 2.3541 | -0.160 ± 0.6340 |
| Platelets, at Baseline | 256.3 ± 48.96 | 301.9 ± 34.84 | 289.5 ± 71.95 |
| Platelets, at Day 2 | 6.6 ± 12.70 | -14.6 ± 12.95 | 1.0 ± 18.48 |
| Platelets, at Day 3 | — | 3.2 ± 19.77 | 0.1 ± 19.63 |
| Platelets, at Day 4 | — | -4.2 ± 17.22 | -4.9 ± 20.16 |
| Platelets, at Day 7 | 1.4 ± 13.65 | 0.0 ± 13.49 | 1.9 ± 23.46 |
| Platelets, at Day 8 | — | 2.8 ± 12.14 | — |
| Platelets, at Day 10 | — | -8.0 ± 19.80 | — |
| Platelets, at Day 14 | 19.9 ± 32.89 | 1.0 ± 52.60 | 2.1 ± 40.86 |
| Platelets, at Week 4 | 30.6 ± 87.1 | -3.5 ± 15.10 | 3.1 ± 31.31 |
| Platelets, at Week 16 | -0.5 ± 19.34 | 6.6 ± 35.49 | -6.4 ± 31.43 |
| Platelets, at Week 24 | 1.1 ± 27.58 | 12.5 ± 37.14 | -2.3 ± 27.79 |
Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of VH3810109.
| Proportion of red blood cells in blood | Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC] | Part 2 Group: VH3810109 60 mg/kg [IV] | Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC] |
|---|---|---|---|
| Baseline | 0.3873 ± 0.04541 | 0.3928 ± 0.04415 | 0.4253 ± 0.04709 |
| Day 2 | 0.0159 ± 0.02226 | 0.0005 ± 0.01513 | 0.0118 ± 0.01704 |
| Day 3 | — | 0.0100 ± 0.02612 | 0.0066 ± 0.01502 |
| Day 4 | — | 0.0003 ± 0.01992 | 0.0023 ± 0.01646 |
| Day 7 | 0.0168 ± 0.01662 | 0.0043 ± 0.01521 | -0.0065 ± 0.01208 |
| Day 8 | — | 0.0062 ± 0.01781 | — |
| Day 10 | — | -0.0270 ± 0.01131 | — |
| Day 14 | 0.0118 ± 0.01426 | -0.0074 ± 0.01736 | -0.0056 ± 0.01420 |
| Week 4 | 0.0016 ± 0.01672 | -0.0013 ± 0.01641 | -0.0069 ± 0.01605 |
| Week 16 | 0.0196 ± 0.02303 | 0.0078 ± 0.02315 | -0.0106 ± 0.00759 |
| Week 24 | 0.0119 ± 0.01389 | 0.0053 ± 0.02437 | -0.0076 ± 0.03243 |
Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of VH3810109.
| Grams per liter (g/L) | Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC] | Part 2 Group: VH3810109 60 mg/kg [IV] | Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC] |
|---|---|---|---|
| Hemoglobin, at Baseline | 131.4 ± 16.78 | 128.3 ± 15.83 | 142.4 ± 15.67 |
| Hemoglobin, at Day 2 | 5.8 ± 6.90 | 1.9 ± 4.61 | 3.9 ± 6.49 |
| Hemoglobin, at Day 3 | — | 6.8 ± 6.79 | 4.3 ± 5.39 |
| Hemoglobin, at Day 4 | — | 4.8 ± 7.19 | 3.9 ± 5.46 |
| Hemoglobin, at Day 7 | 2.6 ± 6.35 | 2.9 ± 5.28 | -0.4 ± 4.37 |
| Hemoglobin, at Day 8 | — | 3.3 ± 4.84 | — |
| Hemoglobin, at Day 10 | — | -10.0 ± 4.24 | — |
| Hemoglobin, at Day 14 | 3.4 ± 4.78 | -0.8 ± 5.90 | -0.4 ± 4.47 |
| Hemoglobin, at Week 4 | 1.0 ± 5.29 | 0.4 ± 6.55 | -1.4 ± 4.96 |
| Hemoglobin, at Week 16 | 4.3 ± 7.23 | 5.3 ± 8.01 | -3.4 ± 4.12 |
| Hemoglobin, at Week 24 | 0.4 ± 4.07 | 4.0 ± 7.54 | -1.4 ± 13.99 |
| Albumin, at Baseline | 44.0 ± 3.02 | 43.9 ± 3.00 | 43.9 ± 3.44 |
| Albumin, at Day 2 | 0.4 ± 2.07 | -2.4 ± 2.45 | -0.3 ± 1.83 |
| Albumin, at Day 3 | — | -0.3 ± 1.86 | -0.1 ± 1.73 |
| Albumin, at Day 4 | — | -0.8 ± 2.40 | 0.3 ± 1.58 |
| Albumin, at Day 7 | 0.1 ± 2.80 | -1.9 ± 1.81 | 0.4 ± 2.00 |
| Albumin, at Day 8 | — | -1.7 ± 1.75 | — |
| Albumin, at Day 10 | — | -5.5 ± 0.71 | — |
| Albumin, at Day 14 | 0.0 ± 2.00 | -1.0 ± 1.51 | -0.1 ± 1.89 |
| Albumin, at Week 4 | -1.4 ± 2.56 | -0.1 ± 2.10 | -0.3 ± 2.43 |
| Albumin, at Week 16 | 0.6 ± 1.77 | 0.8 ± 2.19 | -2.0 ± 2.16 |
| Albumin, at Week 24 | -1.5 ± 2.14 | -0.3 ± 1.04 | -1.9 ± 2.48 |
| Total Protein, at Baseline | 70.0 ± 3.85 | 71.0 ± 3.66 | 72.3 ± 4.40 |
| Total Protein, at Day 2 | 0.6 ± 4.17 | -1.4 ± 4.17 | -1.5 ± 3.51 |
| Total Protein, at Day 3 | — | 1.3 ± 3.93 | -1.9 ± 3.04 |
| Total Protein, at Day 4 | — | 0.0 ± 4.43 | 0.6 ± 2.20 |
| Total Protein, at Day 7 | 0.0 ± 4.57 | -2.8 ± 2.76 | -0.1 ± 3.52 |
| Total Protein, at Day 8 | — | 2.76 ± 2.86 | — |
| Total Protein, at Day 10 | — | -8.0 ± 0.00 | — |
| Total Protein, at Day 14 | 0.0 ± 4.14 | -1.6 ± 2.56 | -0.8 ± 2.71 |
| Total Protein, at Week 4 | -0.6 ± 3.16 | -1.0 ± 3.38 | -1.9 ± 3.14 |
| Total Protein, at Week 16 | 0.9 ± 2.42 | 1.0 ± 3.85 | -4.4 ± 3.87 |
| Total Protein, at Week 24 | -3.4 ± 3.96 | 0.1 ± 2.17 | -2.7 ± 4.46 |
Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of VH3810109.
| Trillion cells/L (TI/L) | Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC] | Part 2 Group: VH3810109 60 mg/kg [IV] | Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC] |
|---|---|---|---|
| Baseline | 4.518 ± 0.5518 | 4.523 ± 0.4014 | 4.889 ± 0.6362 |
| Day 2 | 0.180 ± 0.2654 | 0.043 ± 0.1717 | 0.141 ± 0.2154 |
| Day 3 | — | 0.163 ± 0.3064 | 0.079 ± 0.1890 |
| Day 4 | — | 0.085 ± 0.2239 | 0.056 ± 0.2169 |
| Day 7 | 0.155 ± 0.2067 | 0.084 ± 0.1584 | -0.074 ± 0.1429 |
| Day 8 | — | 0.088 ± 0.1877 | — |
| Day 10 | — | -0.315 ± 0.1626 | — |
| Day 14 | 0.130 ± 0.1646 | -0.088 ± 0.1940 | -0.064 ± 0.1686 |
| Week 4 | 0.050 ± 0.1802 | -0.026 ± 0.1625 | -0.078 ± 0.1814 |
| Week 16 | 0.186 ± 0.2612 | 0.124 ± 0.2212 | -0.164 ± 0.0752 |
| Week 24 | 0.063 ± 0.1496 | 0.078 ± 0.2326 | -0.110 ± 0.3089 |
Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of VH3810109.
| cubic microns | Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC] | Part 2 Group: VH3810109 60 mg/kg [IV] | Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC] |
|---|---|---|---|
| Baseline | 85.78 ± 2.013 | 86.89 ± 6.081 | 87.28 ± 3.478 |
| Day 2 | 0.14 ± 0.466 | -0.66 ± 0.478 | -0.03 ± 0.354 |
| Day 3 | — | -0.72 ± 0.492 | -0.03 ± 0.345 |
| Day 4 | — | -1.38 ± 0.542 | -0.41 ± 0.589 |
| Day 7 | 0.84 ± 0.661 | -0.61 ± 0.562 | -0.10 ± 0.469 |
| Day 8 | — | -0.27 ± 0.674 | — |
| Day 10 | — | 0.05 ± 0.354 | — |
| Day 14 | 0.06 ± 0.784 | 0.04 ± 0.746 | 0.06 ± 0.623 |
| Week 4 | -0.53 ± 1.216 | 0.34 ± 1.125 | -0.03 ± 0.703 |
| Week 16 | 0.76 ± 0.842 | -0.75 ± 2.522 | 0.74 ± 1.078 |
| Week 24 | 1.34 ± 1.983 | -0.41 ± 2.107 | 0.40 ± 2.195 |
Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of VH3810109.
| picograms (pg) | Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC] | Part 2 Group: VH3810109 60 mg/kg [IV] | Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC] |
|---|---|---|---|
| Baseline | 29.05 ± 1.028 | 28.33 ± 2.213 | 29.26 ± 1.660 |
| Day 2 | 0.20 ± 0.553 | 0.21 ± 0.458 | -0.08 ± 0.345 |
| Day 3 | — | 0.63 ± 0.836 | 0.39 ± 0.290 |
| Day 4 | — | 0.67 ± 0.463 | 0.55 ± 0.678 |
| Day 7 | -0.36 ± 0.302 | 0.16 ± 0.385 | 0.29 ± 0.536 |
| Day 8 | — | 0.27 ± 0.480 | — |
| Day 10 | — | -0.20 ± 0.141 | — |
| Day 14 | -0.06 ± 0.475 | 0.44 ± 0.524 | 0.33 ± 0.590 |
| Week 4 | -0.09 ± 0.608 | 0.39 ± 0.617 | 0.16 ± 0.466 |
| Week 16 | -0.21 ± 0.613 | 0.39 ± 0.779 | 0.24 ± 0.737 |
| Week 24 | -0.39 ± 1.051 | 0.39 ± 0.716 | 0.31 ± 1.524 |
Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of VH3810109.
| milligram per deciliter (mg/dL) | Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC] | Part 2 Group: VH3810109 60 mg/kg [IV] | Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC] |
|---|---|---|---|
| Glucose, at Baseline | 5.009778 ± 0.2649736 | 5.037533 ± 0.2582430 | 4.864064 ± 0.2032812 |
| Glucose, at Day 2 | -0.006939 ± 0.2306696 | 0.256734 ± 0.5881647 | 0.145714 ± 0.2966207 |
| Glucose, at Day 3 | — | -0.018503 ± 0.2930311 | 0.201224 ± 0.3645321 |
| Glucose, at Day 4 | — | -0.027755 ± 0.2868315 | -0.006939 ± 0.2852734 |
| Glucose, at Day 7 | 0.180408 ± 0.1723749 | 0.548161 ± 1.1531574 | 0.166530 ± 0.3408978 |
| Glucose, at Day 8 | — | -0.111020 ± 0.3330600 | — |
| Glucose, at Day 10 | — | 0.000000 ± 0.1570060 | — |
| Glucose, at Day 14 | -0.027755 ± 0.2586688 | 0.048571 ± 0.3884992 | 0.006939 ± 0.2790329 |
| Glucose, at Week 4 | 0.027755 ± 0.3857275 | -0.124898 ± 0.2842106 | 0.215101 ± 0.5168587 |
| Glucose, at Week 16 | -0.180408 ± 0.2254827 | 0.076326 ± 0.2138345 | 0.111020 ± 0.3376541 |
| Glucose, at Week 24 | -0.249795 ± 0.3040408 | -0.208163 ± 0.3557469 | 0.237900 ± 0.3184202 |
| Blood urea nitrogen, at Baseline | 3.83775 ± 0.731134 | 4.19475 ± 1.376981 | 4.73025 ± 1.594955 |
| Blood urea nitrogen, at Day 2 | 1.21380 ± 0.678703 | 0.39270 ± 0.937762 | 0.27221 ± 1.307383 |
| Blood urea nitrogen, at Day 3 | — | 0.67830 ± 0.651268 | 0.16511 ± 1.369415 |
| Blood urea nitrogen, at Day 4 | — | 0.82705 ± 0.927490 | 0.15619 ± 1.726718 |
| Blood urea nitrogen, at Day 7 | 0.30345 ± 1.042747 | 0.58459 ± 1.250583 | -0.42840 ± 1.421995 |
| Blood urea nitrogen, at Day 8 | — | 0.55930 ± 0.809900 | — |
| Blood urea nitrogen, at Day 10 | — | 0.35700 ± 0.000000 | — |
| Blood urea nitrogen, at Day 14 | 0.02678 ± 0.714446 | -0.33915 ± 1.192768 | -0.50873 ± 1.656633 |
| Blood urea nitrogen, at Week 4 | 0.31684 ± 0.895135 | -0.16065 ± 0.695659 | -0.24098 ± 1.082288 |
| Blood urea nitrogen, at Week 16 | 0.21420 ± 1.260309 | -0.41948 ± 0.805711 | 0.03060 ± 1.359639 |
| Blood urea nitrogen, at Week 24 | 0.32576 ± 1.074638 | 0.26775 ± 1.474420 | -0.05610 ± 1.187055 |
| Creatinine, at Baseline | 68.2890 ± 15.18504 | 68.0680 ± 13.56381 | 73.8140 ± 15.20157 |
| Creatinine, at Day 2 | 1.4365 ± 8.05969 | -3.2045 ± 3.97975 | 2.3205 ± 9.02667 |
| Creatinine, at Day 3 | — | -0.7367 ± 6.16058 | 3.6465 ± 5.49905 |
| Creatinine, at Day 4 | — | -0.5893 ± 6.03887 | 0.8840 ± 7.94898 |
| Creatinine, at Day 7 | 0.0000 ± 5.84472 | 2.4310 ± 6.71158 | 6.2985 ± 9.30077 |
| Creatinine, at Day 8 | — | -0.4420 ± 6.01510 | — |
| Creatinine, at Day 10 | — | 11.9340 ± 3.12541 | — |
| Creatinine, at Day 14 | 0.1105 ± 3.82236 | 0.6630 ± 6.49175 | 3.4255 ± 5.98510 |
| Creatinine, at Week 4 | 2.9835 ± 7.05521 | 0.1105 ± 4.18485 | 2.7625 ± 6.78911 |
| Creatinine, at Week 16 | -0.3315 ± 6.87895 | -0.7735 ± 7.98314 | 3.1571 ± 5.32501 |
| Creatinine, at Week 24 | 2.0995 ± 4.25102 | -0.2210 ± 5.62574 | 5.6829 ± 7.60201 |
| Direct Bilirubin, at Baseline | 2.0306 ± 0.49592 | 1.7741 ± 0.62621 | 2.1161 ± 1.04191 |
| Direct Bilirubin, at Day 2 | -0.5771 ± 0.42811 | -0.2138 ± 0.45473 | -0.0214 ± 0.44250 |
| Direct Bilirubin, at Day 3 | — | -0.1425 ± 0.45134 | -0.1069 ± 0.43776 |
| Direct Bilirubin, at Day 4 | — | 0.0285 ± 0.47656 | 0.1283 ± 0.58348 |
| Direct Bilirubin, at Day 7 | 0.0000 ± 0.43836 | 0.0214 ± 0.42320 | -0.1283 ± 0.33893 |
| Direct Bilirubin, at Day 8 | — | 0.1995 ± 0.53440 | — |
| Direct Bilirubin, at Day 10 | — | -0.5130 ± 0.48366 | — |
| Direct Bilirubin, at Day 14 | -0.2351 ± 0.57763 | -0.3634 ± 0.46997 | -0.1710 ± 0.44778 |
| Direct Bilirubin, at Week 4 | -0.5344 ± 0.62287 | 0.0000 ± 0.42872 | -0.1496 ± 0.50427 |
| Direct Bilirubin, at Week 16 | -0.3206 ± 0.59544 | -0.2138 ± 0.52308 | -0.7817 ± 0.56591 |
| Direct Bilirubin, at Week 24 | -0.3420 ± 0.49222 | -0.2565 ± 0.61993 | -0.3176 ± 0.36178 |
| Total bilirubin, at Baseline | 9.7684 ± 3.95623 | 10.4738 ± 3.28512 | 12.5258 ± 7.47987 |
| Total bilirubin, at Day 2 | -1.9879 ± 2.22382 | -1.1115 ± 3.08613 | 0.6413 ± 2.98813 |
| Total bilirubin, at Day 3 | — | -0.8550 ± 2.99128 | 0.4061 ± 3.48526 |
| Total bilirubin, at Day 4 | — | 0.0570 ± 2.84018 | 2.0306 ± 4.64850 |
| Total bilirubin, at Day 7 | 1.6031 ± 2.82603 | -0.2565 ± 3.16102 | -0.4703 ± 2.08181 |
| Total bilirubin, at Day 8 | — | 0.9405 ± 3.54057 | — |
| Total bilirubin, at Day 10 | — | -2.3085 ± 1.81373 | — |
| Total bilirubin, at Day 14 | 0.6199 ± 3.02728 | -2.4368 ± 2.07377 | -0.6199 ± 3.52222 |
| Total bilirubin, at Week 4 | -1.7528 ± 3.77392 | -1.1115 ± 1.51851 | -0.3206 ± 3.67145 |
| Total bilirubin, at Week 16 | -0.4061 ± 3.45758 | -1.5390 ± 2.90772 | -2.4917 ± 2.46196 |
| Total bilirubin, at Week 24 | 0.0428 ± 2.98813 | -0.6840 ± 3.10368 | -1.6856 ± 2.63700 |
Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of VH3810109.
| Millimole per liter (mmol/L) | Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC] | Part 2 Group: VH3810109 60 mg/kg [IV] | Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC] |
|---|---|---|---|
| Calcium, at Baseline | 2.329706 ± 0.1049575 | 2.317231 ± 0.0805028 | 2.351538 ± 0.0931159 |
| Calcium, at Day 2 | -0.015594 ± 0.1041067 | -0.003119 ± 0.0983979 | -0.003119 ± 0.0983979 |
| Calcium, at Day 3 | — | 0.037425 ± 0.1101762 | 0.003119 ± 0.0759557 |
| Calcium, at Day 4 | — | 0.008317 ± 0.1145166 | 0.040544 ± 0.0729700 |
| Calcium, at Day 7 | -0.012475 ± 0.0533453 | -0.006238 ± 0.0830180 | 0.037425 ± 0.0442316 |
| Calcium, at Day 8 | — | -0.004158 ± 0.0639356 | — |
| Calcium, at Day 10 | — | -0.112275 ± 0.0882116 | — |
| Calcium, at Day 14 | 0.009356 ± 0.0398698 | -0.034306 ± 0.0923367 | -0.009356 ± 0.0923367 |
| Calcium, at Week 4 | -0.031188 ± 0.0739536 | -0.034306 ± 0.0853291 | 0.003119 ± 0.0826826 |
| Calcium, at Week 16 | -0.015594 ± 0.0842805 | 0.018713 ± 0.0751464 | -0.064157 ± 0.0496021 |
| Calcium, at Week 24 | -0.056138 ± 0.0861717 | -0.031188 ± 0.0371268 | -0.053464 ± 0.1002445 |
| Carbon Dioxide, at Baseline | 29.4 ± 1.77 | 27.8 ± 2.25 | 28.6 ± 1.92 |
| Carbon Dioxide, at Day 2 | 0.5 ± 1.41 | 0.6 ± 1.19 | 0.4 ± 1.41 |
| Carbon Dioxide, at Day 3 | — | 1.5 ± 0.84 | -0.5 ± 0.93 |
| Carbon Dioxide, at Day 4 | — | 1.3 ± 1.03 | 0.3 ± 1.28 |
| Carbon Dioxide, at Day 7 | -0.3 ± 1.39 | 0.3 ± 1.28 | 0.3 ± 0.71 |
| Carbon Dioxide, at Day 8 | — | 1.3 ± 1.03 | — |
| Carbon Dioxide, at Day 10 | — | 0.0 ± 1.41 | — |
| Carbon Dioxide, at Day 14 | 0.3 ± 0.89 | 0.5 ± 1.51 | -0.4 ± 1.41 |
| Carbon Dioxide, at Week 4 | 1.5 ± 1.51 | 0.9 ± 1.64 | 0.0 ± 0.93 |
| Carbon Dioxide, at Week 16 | -1.3 ± 1.28 | 0.3 ± 0.71 | -0.4 ± 0.98 |
| Carbon Dioxide, at Week 24 | -0.5 ± 1.20 | 0.4 ± 1.51 | 0.3 ± 1.38 |
| Chloride, at Baseline | 103.1 ± 1.81 | 102.1 ± 2.59 | 102.4 ± 2.20 |
| Chloride, at Day 2 | -0.6 ± 2.45 | 0.0 ± 2.00 | 0.1 ± 2.42 |
| Chloride, at Day 3 | — | -1.2 ± 1.94 | -0.3 ± 2.49 |
| Chloride, at Day 4 | — | -1.5 ± 1.64 | -0.4 ± 2.39 |
| Chloride, at Day 7 | -0.5 ± 1.07 | 0.1 ± 1.64 | 0.5 ± 2.14 |
| Chloride, at Day 8 | — | 0.3 ± 1.75 | — |
| Chloride, at Day 10 | — | 5.5 ± 2.12 | — |
| Chloride, at Day 14 | -1.6 ± 1.77 | 1.0 ± 2.56 | 0.4 ± 2.13 |
| Chloride, at Week 4 | -1.3 ± 2.38 | 1.1 ± 2.47 | 0.4 ± 1.06 |
| Chloride, at Week 16 | -0.4 ± 2.13 | 1.5 ± 1.41 | 0.7 ± 1.80 |
| Chloride, at Week 24 | -0.1 ± 2.36 | 0.6 ± 2.26 | 1.7 ± 2.21 |
| Potassium, at Baseline | 4.36 ± 0.484 | 4.14 ± 0.342 | 4.29 ± 0.485 |
| Potassium, at Day 2 | 0.09 ± 0.242 | 0.16 ± 0.325 | 0.10 ± 0.366 |
| Potassium, at Day 3 | — | 0.13 ± 0.372 | 0.14 ± 0.250 |
| Potassium, at Day 4 | — | 0.00 ± 0.544 | 0.13 ± 0.320 |
| Potassium, at Day 7 | -0.30 ± 0.421 | 0.29 ± 0.470 | -0.01 ± 0.340 |
| Potassium, at Day 8 | — | 0.07 ± 0.207 | — |
| Potassium, at Day 10 | — | 0.45 ± 0.354 | — |
| Potassium, at Day 14 | -0.13 ± 0.381 | 0.04 ± 0.513 | 0.09 ± 0.458 |
| Potassium, at Week 4 | -0.16 ± 0.389 | 0.18 ± 0.183 | -0.01 ± 0.196 |
| Potassium, at Week 16 | -0.38 ± 0.413 | 0.11 ± 0.189 | -0.04 ± 0.382 |
| Potassium, at Week 24 | -0.06 ± 0.245 | -0.03 ± 0.354 | 0.01 ± 0.308 |
| Sodium, at Baseline | 138.8 ± 1.39 | 137.1 ± 2.23 | 136.9 ± 2.53 |
| Sodium, at Day 2 | -0.4 ± 2.13 | -0.4 ± 2.26 | 0.1 ± 2.30 |
| Sodium, at Day 3 | — | -0.8 ± 0.98 | -0.3 ± 1.49 |
| Sodium, at Day 4 | — | -1.3 ± 2.25 | -0.1 ± 1.89 |
| Sodium, at Day 7 | -0.5 ± 1.77 | 0.5 ± 2.20 | 0.8 ± 1.98 |
| Sodium, at Day 8 | — | 0.3 ± 1.51 | — |
| Sodium, at Day 10 | — | 4.5 ± 4.95 | — |
| Sodium, at Day 14 | -1.3 ± 1.39 | 1.0 ± 2.88 | 0.6 ± 1.85 |
| Sodium, at Week 4 | -0.9 ± 2.17 | 1.0 ± 2.45 | 0.9 ± 1.64 |
| Sodium, at Week 16 | -0.8 ± 1.58 | 1.0 ± 2.51 | 1.3 ± 1.60 |
| Sodium, at Week 24 | -1.1 ± 2.53 | 0.1 ± 3.48 | 2.0 ± 2.24 |
Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of VH3810109.
| International Units per liter (IU/L) | Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC] | Part 2 Group: VH3810109 60 mg/kg [IV] | Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC] |
|---|---|---|---|
| ALT, at Baseline | 11.8 ± 2.71 | 12.5 ± 4.00 | 20.0 ± 8.09 |
| ALT, at Day 2 | 0.6 ± 1.69 | -0.5 ± 1.31 | -1.8 ± 3.45 |
| ALT, at Day 3 | — | 0.5 ± 1.52 | -1.1 ± 4.61 |
| ALT, at Day 4 | — | 0.5 ± 2.43 | -0.8 ± 6.14 |
| ALT, at Day 7 | 1.5 ± 2.83 | 0.5 ± 2.73 | 2.0 ± 7.91 |
| ALT, at Day 8 | — | 0.8 ± 3.76 | — |
| ALT, at Day 10 | — | -1.0 ± 1.41 | — |
| ALT, at Day 14 | 1.0 ± 1.41 | 0.6 ± 2.13 | -2.0 ± 5.81 |
| ALT, at Week 4 | 4.3 ± 6.34 | 1.6 ± 3.66 | -1.9 ± 8.18 |
| ALT, at Week 16 | 4.4 ± 2.72 | 1.4 ± 2.45 | -0.1 ± 7.06 |
| ALT, at Week 24 | 2.0 ± 4.44 | 1.3 ± 5.70 | -1.3 ± 5.96 |
| AST, at Baseline | 14.5 ± 2.39 | 16.0 ± 2.98 | 18.1 ± 2.64 |
| AST, at Day 2 | 0.4 ± 2.00 | 1.4 ± 1.77 | -1.8 ± 3.06 |
| AST, at Day 3 | — | 2.7 ± 1.63 | -0.6 ± 3.42 |
| AST, at Day 4 | — | 1.8 ± 1.72 | 0.5 ± 3.66 |
| AST, at Day 7 | 2.8 ± 2.82 | 0.8 ± 3.06 | 2.5 ± 3.74 |
| AST, at Day 8 | — | 1.0 ± 3.03 | — |
| AST, at Day 10 | — | -2.5 ± 0.71 | — |
| AST, at Day 14 | 1.9 ± 2.03 | 1.8 ± 2.76 | -0.9 ± 3.40 |
| AST, at Week 4 | 3.0 ± 3.51 | 4.3 ± 8.96 | 0.0 ± 4.38 |
| AST, at Week 16 | 2.9 ± 1.81 | 1.1 ± 3.14 | 0.4 ± 3.95 |
| AST, at Week 24 | 2.0 ± 4.78 | 0.1 ± 2.47 | -0.7 ± 2.63 |
| ALP, at Baseline | 54.6 ± 8.99 | 55.9 ± 20.00 | 57.1 ± 9.30 |
| ALP, at Day 2 | 2.9 ± 3.83 | 0.6 ± 4.50 | -2.4 ± 4.44 |
| ALP, at Day 3 | — | 4.7 ± 4.03 | 0.0 ± 4.81 |
| ALP, at Day 4 | — | 4.0 ± 5.83 | 3.0 ± 3.89 |
| ALP, at Day 7 | 4.6 ± 2.77 | 5.9 ± 4.05 | 4.9 ± 5.33 |
| ALP, at Day 8 | — | 6.8 ± 5.04 | — |
| ALP, at Day 10 | — | -1.5 ± 4.95 | — |
| ALP, at Day 14 | 7.6 ± 2.97 | 4.4 ± 4.17 | 2.8 ± 4.71 |
| ALP, at Week 4 | 0.6 ± 6.50 | 7.9 ± 4.52 | -1.8 ± 2.76 |
| ALP, at Week 16 | 4.8 ± 5.23 | 5.4 ± 5.42 | 1.0 ± 5.39 |
| ALP, at Week 24 | -0.1 ± 5.17 | 3.3 ± 5.85 | 1.6 ± 4.89 |
Urine samples were collected as assessed by protocol, at specific time points for laboratory analysis of VH3810109. At baseline and post-baseline, worst case urinalysis data was determined by comparing the resulted values of the urinalysis for each participant to the normal rage. This endpoint evaluates the changes from baseline for the worst case urinalysis.
| Participants | Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC] | Part 2 Group: VH3810109 60 mg/kg [IV] | Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC] |
|---|---|---|---|
| Glucose | 1 | 0 | 0 |
| Protein | 0 | 1 | 1 |
| Leukocyte esterase | 0 | 1 | 1 |
ECG values were collected as assessed by protocol, at the indicated time points.
| Miliseconds | Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC] | Part 2 Group: VH3810109 60 mg/kg [IV] | Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC] |
|---|---|---|---|
| PR Interval, at Baseline | 161.375 ± 20.2762 | 164.000 ± 16.6733 | 164.875 ± 14.2872 |
| PR Interval, at Day 1 | -4.000 ± 10.7157 | — | 0.500 ± 4.5145 |
| PR Interval, at Day 2 | -0.208 ± 7.5297 | 1.917 ± 9.5282 | 3.500 ± 7.6677 |
| PR Interval, at Day 3 | 1.083 ± 7.8493 | 3.000 ± 10.6354 | 3.667 ± 10.6845 |
| PR Interval, at Day 4 | 4.625 ± 8.6179 | 0.875 ± 10.8656 | 3.000 ± 10.0775 |
| PR Interval, at Day 7 | 1.458 ± 11.6223 | 6.167 ± 10.9516 | 2.625 ± 6.3507 |
| PR Interval, at Day 8 | — | 5.875 ± 9.4330 | — |
| PR Interval, at Day 10 | — | 19.167 ± 8.7210 | — |
| PR Interval, at Week 4 | 9.542 ± 5.9038 | 4.250 ± 11.7700 | -2.250 ± 10.6231 |
| PR Interval, at Week 24 | 4.583 ± 10.1164 | -0.958 ± 11.6571 | -1.905 ± 12.0872 |
| QRS Interval, at Baseline | 92.875 ± 8.1141 | 90.750 ± 11.8291 | 100.250 ± 12.1155 |
| QRS Interval, at Day 1 | 0.875 ± 3.5587 | — | -5.250 ± 6.8098 |
| QRS Interval, at Day 2 | -2.292 ± 2.6693 | -0.458 ± 3.7116 | -3.708 ± 5.6833 |
| QRS Interval, at Day 3 | -0.875 ± 2.3363 | -2.833 ± 6.2463 | -2.583 ± 3.6764 |
| QRS Interval, at Day 4 | 1.458 ± 5.0895 | -1.875 ± 6.0708 | -4.458 ± 6.4855 |
| QRS Interval, at Day 7 | 0.000 ± 5.1052 | -1.500 ± 6.8359 | -2.917 ± 6.3164 |
| QRS Interval, at Day 8 | — | -1.042 ± 4.6987 | — |
| QRS Interval, at Day 10 | — | -4.333 ± 6.5997 | — |
| QRS Interval, at Week 4 | 0.708 ± 3.9337 | -0.958 ± 3.8398 | -4.708 ± 6.2372 |
| QRS Interval, at Week 24 | -0.917 ± 4.5066 | -0.458 ± 4.4755 | -5.238 ± 6.4599 |
| QT Interval, at Baseline | 378.875 ± 17.7719 | 395.875 ± 19.1493 | 380.375 ± 12.3513 |
| QT Interval, at Day 1 | 0.708 ± 12.1713 | — | -0.625 ± 8.6620 |
| QT Interval, at Day 2 | 4.750 ± 12.1299 | 20.750 ± 18.9684 | 16.083 ± 13.6449 |
| QT Interval, at Day 3 | 8.583 ± 18.2650 | 10.542 ± 27.0566 | 9.792 ± 12.7179 |
| QT Interval, at Day 4 | 5.917 ± 22.1616 | 7.000 ± 27.0725 | 9.167 ± 18.5267 |
| QT Interval, at Day 7 | 7.042 ± 20.7972 | 21.083 ± 21.4755 | 8.500 ± 13.6498 |
| QT Interval, at Day 8 | — | 19.167 ± 20.0206 | — |
| QT Interval, at Day 10 | — | 31.667 ± 55.1543 | — |
| QT Interval, at Week 4 | 14.083 ± 18.0614 | 31.167 ± 17.0023 | 10.583 ± 13.7318 |
| QT Interval, at Week 24 | 15.125 ± 21.3348 | 13.167 ± 21.5318 | 15.952 ± 10.9771 |
| QTcF Interval, at Baseline | 402.750 ± 10.5119 | 419.375 ± 13.7523 | 397.000 ± 14.8131 |
| QTcF Interval, at Day 1 | 2.833 ± 10.0570 | — | 1.375 ± 9.1780 |
| QTcF Interval, at Day 2 | -1.875 ± 9.2923 | 1.083 ± 15.4486 | 3.375 ± 11.7924 |
| QTcF Interval, at Day 3 | 0.917 ± 9.5232 | -1.250 ± 14.9047 | 2.083 ± 8.6295 |
| QTcF Interval, at Day 4 | -2.000 ± 15.0449 | -4.292 ± 18.3220 | 1.917 ± 9.0847 |
| QTcF Interval, at Day 7 | 8.667 ± 22.8341 | 0.958 ± 9.6715 | 3.500 ± 11.9004 |
| QTcF Interval, at Day 8 | — | 1.833 ± 14.8410 | — |
| QTcF Interval, at Day 10 | — | 0.667 ± 33.9411 | — |
| QTcF Interval, at Week 4 | 1.167 ± 10.6398 | 6.500 ± 8.8515 | 2.250 ± 8.4867 |
| QTcF Interval, at Week 24 | 2.417 ± 10.5991 | 2.229 ± 14.8754 | 7.238 ± 5.6461 |
Temperature was measured at the indicated time points, in a supine position after the participant has been at rest for at least 5 minutes in a quiet setting without distractions.
| Degrees Celcius | Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC] | Part 2 Group: VH3810109 60 mg/kg [IV] | Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC] |
|---|---|---|---|
| Baseline | 36.54 ± 0.233 | 36.79 ± 0.344 | 36.49 ± 0.500 |
| Day 2 | -0.10 ± 0.424 | -0.48 ± 0.437 | -0.14 ± 0.342 |
| Day 3 | -0.23 ± 0.365 | -0.50 ± 0.475 | -0.25 ± 0.454 |
| Day 4 | -0.03 ± 0.311 | -0.41 ± 0.569 | -0.20 ± 0.463 |
| Day 7 | -0.05 ± 0.524 | -0.41 ± 0.622 | -0.04 ± 0.578 |
| Day 8 | — | -0.41 ± 0.599 | — |
| Day 10 | — | -0.60 ± 0.566 | — |
| Day 14 | -0.13 ± 0.392 | -0.28 ± 0.492 | -0.28 ± 0.453 |
| Day 21 | -0.11 ± 0.554 | -0.49 ± 0.352 | -0.04 ± 0.469 |
| Week 4 | -0.21 ± 0.364 | -0.56 ± 0.534 | -0.09 ± 0.549 |
| Week 8 | -0.28 ± 0.399 | -0.45 ± 0.535 | -0.20 ± 0.566 |
| Week 12 | -0.23 ± 0.271 | -0.33 ± 0.607 | -0.28 ± 0.423 |
| Week 16 | -0.34 ± 0.346 | -0.33 ± 0.575 | -0.69 ± 0.534 |
| Week 20 | -0.17 ± 0.315 | -0.40 ± 0.414 | -0.19 ± 0.505 |
| Week 24 | -0.19 ± 0.364 | -0.55 ± 0.678 | 0.09 ± 0.367 |
Pulse rate was measured at the indicated time points, in a supine position after the participant has been at rest for at least 5 minutes in a quiet setting without distractions.
| Beats per minute (Beats/min) | Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC] | Part 2 Group: VH3810109 60 mg/kg [IV] | Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC] |
|---|---|---|---|
| Baseline | 73.9 ± 7.85 | 71.1 ± 7.16 | 75.9 ± 12.26 |
| Day 2 | -4.4 ± 6.74 | -7.6 ± 8.28 | -13.8 ± 10.66 |
| Day 3 | -7.6 ± 4.84 | -5.4 ± 9.01 | -12.1 ± 8.63 |
| Day 4 | -6.4 ± 7.76 | -4.3 ± 8.75 | -8.1 ± 11.52 |
| Day 7 | -1.4 ± 18.68 | -9.4 ± 6.95 | -8.4 ± 14.81 |
| Day 8 | — | -8.3 ± 5.78 | — |
| Day 10 | — | -12.0 ± 7.07 | — |
| Day 14 | -4.5 ± 7.60 | -10.0 ± 6.72 | -11.4 ± 16.95 |
| Day 21 | -3.1 ± 11.43 | -9.1 ± 5.06 | -11.0 ± 18.45 |
| Week 4 | -7.3 ± 3.28 | -9.9 ± 7.34 | -13.4 ± 12.05 |
| Week 8 | -3.9 ± 15.13 | -8.0 ± 8.09 | -8.3 ± 15.75 |
| Week 12 | -4.8 ± 10.44 | -6.3 ± 7.44 | -9.8 ± 14.21 |
| Week 16 | -11.1 ± 10.25 | -5.1 ± 8.61 | -10.6 ± 10.66 |
| Week 20 | -9.0 ± 8.14 | -5.0 ± 5.01 | -12.4 ± 8.06 |
| Week 24 | -10.5 ± 6.57 | -4.3 ± 4.80 | -15.3 ± 11.50 |
Respiratory rate was measured at the indicated time points, in a supine position after the participant has been at rest for at least 5 minutes in a quiet setting without distractions.
| Breaths per minute (Breaths/min) | Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC] | Part 2 Group: VH3810109 60 mg/kg [IV] | Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC] |
|---|---|---|---|
| Baseline | 15.5 ± 1.41 | 15.8 ± 3.77 | 13.8 ± 1.98 |
| Day 1/4 Hours Postdose | -1.4 ± 1.90 | -0.3 ± 3.45 | 2.0 ± 3.38 |
| Day 1/8 Hours Postdose | 1.5 ± 2.56 | -2.3 ± 2.25 | 0.8 ± 3.85 |
| Day 2 | -1.3 ± 3.20 | -2.0 ± 3.85 | 1.3 ± 2.12 |
| Day 3 | -1.3 ± 2.12 | -1.5 ± 4.24 | 2.3 ± 2.71 |
| Day 4 | -2.0 ± 2.14 | -1.5 ± 3.16 | 0.0 ± 2.62 |
| Day 7 | 0.8 ± 4.77 | -2.8 ± 4.89 | -0.3 ± 2.92 |
| Day 8 | — | -0.8 ± 5.01 | — |
| Day 10 | — | 0.0 ± 5.66 | — |
| Day 14 | -1.5 ± 2.98 | -2.0 ± 3.38 | -1.3 ± 2.12 |
| Day 21 | -1.3 ± 2.60 | -2.3 ± 2.92 | 1.0 ± 3.85 |
| Week 4 | 1.3 ± 2.38 | -2.0 ± 4.41 | 1.0 ± 2.83 |
| Week 8 | 1.0 ± 2.83 | -2.3 ± 4.59 | 1.3 ± 1.83 |
| Week 12 | -1.0 ± 2.14 | -2.5 ± 3.34 | 1.5 ± 2.33 |
| Week 16 | -2.0 ± 4.28 | -2.5 ± 5.42 | 3.1 ± 1.95 |
| Week 20 | -0.9 ± 3.80 | -1.0 ± 3.21 | 1.1 ± 3.98 |
| Week 24 | -3.3 ± 2.38 | -2.5 ± 1.77 | 0.3 ± 2.93 |
Blood pressure was measured at the indicated time points, in a supine position after the participant has been at rest for at least 5 minutes in a quiet setting without distractions.
| Millimeters of mercury (mmHg) | Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC] | Part 2 Group: VH3810109 60 mg/kg [IV] | Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC] |
|---|---|---|---|
| Systolic Blood Pressure, at Baseline | 112.8 ± 12.67 | 106.3 ± 11.68 | 114.4 ± 9.50 |
| Systolic Blood Pressure, at Day 2 | -4.1 ± 12.24 | 3.5 ± 8.04 | -4.5 ± 7.19 |
| Systolic Blood Pressure, at Day 3 | -2.9 ± 7.49 | 0.8 ± 5.99 | -4.5 ± 4.66 |
| Systolic Blood Pressure, at Day 4 | -0.5 ± 9.20 | 0.3 ± 6.45 | -5.6 ± 6.23 |
| Systolic Blood Pressure, at Day 7 | 2.1 ± 8.18 | 2.1 ± 6.03 | 3.6 ± 8.28 |
| Systolic Blood Pressure, at Day 8 | — | -2.4 ± 8.47 | — |
| Systolic Blood Pressure, at Day 10 | — | 4.5 ± 13.44 | — |
| Systolic Blood Pressure, at Day 14 | 2.4 ± 8.68 | 11.3 ± 9.19 | 6.5 ± 10.38 |
| Systolic Blood Pressure, at Day 21 | 5.4 ± 10.21 | 9.8 ± 13.36 | 7.8 ± 11.50 |
| Systolic Blood Pressure, at Week 4 | -0.9 ± 8.54 | 9.5 ± 11.80 | 2.8 ± 7.85 |
| Systolic Blood Pressure, at Week 8 | 9.0 ± 17.02 | 9.5 ± 14.43 | 5.6 ± 7.58 |
| Systolic Blood Pressure, at Week 12 | -3.8 ± 4.89 | 4.5 ± 16.38 | 7.9 ± 11.54 |
| Systolic Blood Pressure, at Week 16 | 4.6 ± 5.55 | 7.9 ± 11.08 | -0.3 ± 10.27 |
| Systolic Blood Pressure, at Week 20 | -2.1 ± 14.28 | 2.1 ± 10.83 | 6.3 ± 7.83 |
| Systolic Blood Pressure, at Week 24 | 2.0 ± 7.78 | 6.4 ± 10.07 | -0.1 ± 4.91 |
| Diastolic Blood Pressure, at Baseline | 66.5 ± 9.71 | 59.8 ± 6.45 | 62.1 ± 5.59 |
| Diastolic Blood Pressure, at Day 2 | -1.6 ± 5.48 | 3.4 ± 8.23 | -0.5 ± 6.89 |
| Diastolic Blood Pressure, at Day 3 | 2.4 ± 4.87 | 1.1 ± 7.24 | -1.9 ± 5.51 |
| Diastolic Blood Pressure, at Day 4 | 0.6 ± 6.05 | -2.3 ± 4.62 | -0.8 ± 4.86 |
| Diastolic Blood Pressure, at Day 7 | 1.9 ± 8.32 | -1.6 ± 4.41 | 9.5 ± 9.78 |
| Diastolic Blood Pressure, at Day 8 | — | -1.8 ± 3.96 | — |
| Diastolic Blood Pressure, at Day 10 | — | 9.0 ± 8.49 | — |
| Diastolic Blood Pressure, at Day 14 | 1.6 ± 6.63 | 6.1 ± 3.72 | 6.1 ± 5.33 |
| Diastolic Blood Pressure, at Day 21 | 2.8 ± 6.50 | 10.6 ± 8.37 | 12.9 ± 4.67 |
| Diastolic Blood Pressure, at Week 4 | 2.1 ± 7.24 | 8.1 ± 6.40 | 7.6 ± 6.32 |
| Diastolic Blood Pressure, at Week 8 | 6.4 ± 7.74 | 9.1 ± 3.44 | 7.6 ± 3.29 |
| Diastolic Blood Pressure, at Week 12 | 0.5 ± 4.96 | 6.8 ± 7.15 | 11.5 ± 7.78 |
| Diastolic Blood Pressure, at Week 16 | 3.8 ± 3.15 | 9.1 ± 5.11 | 8.4 ± 6.73 |
| Diastolic Blood Pressure, at Week 20 | -2.0 ± 7.09 | 6.3 ± 5.55 | 13.6 ± 6.19 |
| Diastolic Blood Pressure, at Week 24 | 1.5 ± 4.28 | 7.4 ± 6.57 | 12.1 ± 7.49 |
Collected over SAEs, all cause mortality and non-SAEs were collected from Day 1 post-administration up to Week 24.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC] | 0/8 (0%) | 0/8 (0%) | 8/8 (100%) |
| Part 2 Group: VH3810109 60 mg/kg [IV] | 0/8 (0%) | 0/8 (0%) | 1/8 (12.5%) |
| Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC] | 0/8 (0%) | 0/8 (0%) | 8/8 (100%) |
| Event | Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC] | Part 2 Group: VH3810109 60 mg/kg [IV] | Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC] |
|---|---|---|---|
| Injection site erythemaGeneral disorders | 7/8 | 0/8 | 8/8 |
| Upper respiratory tract infectionInfections and infestations | 2/8 | 0/8 | 1/8 |
| Injection site painGeneral disorders | 1/8 | 0/8 | 2/8 |
| Injection site bruisingGeneral disorders | 0/8 | 0/8 | 2/8 |
| NasopharyngitisInfections and infestations | 0/8 | 0/8 | 2/8 |
| HeadacheNervous system disorders | 1/8 | 0/8 | 0/8 |
| Injection site pruritusGeneral disorders | 1/8 | 0/8 | 0/8 |
| Muscle tightnessMusculoskeletal and connective tissue disorders | 1/8 | 1/8 | 0/8 |
| ParaesthesiaNervous system disorders | 1/8 | 0/8 | 0/8 |
| Post-traumatic painInjury, poisoning and procedural complications | 1/8 | 0/8 | 0/8 |
| Age, Continuous(Years) | Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC] | Part 2 Group: VH3810109 60 mg/kg [IV] | Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC] | Total |
|---|---|---|---|---|
| Mean | 42.8 ± 7.76 | 40.0 ± 14.45 | 39.9 ± 10.59 | 40.87 ± 10.85 |
| Sex: Female, Male(Participants) | Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC] | Part 2 Group: VH3810109 60 mg/kg [IV] | Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC] | Total |
|---|---|---|---|---|
| Female | 5 | 7 | 3 | 15 |
| Male | 3 | 1 | 5 | 9 |
| Race/Ethnicity, Customized(Participants) | Part 1 Group: VH3810109 20 mg/kg + rHuPH20 [SC] | Part 2 Group: VH3810109 60 mg/kg [IV] | Part 3 Group: VH3810109 3000 mg + rHuPH20 [SC] | Total |
|---|---|---|---|---|
| Asian | 2 | 1 | 1 | 4 |
| Black or African American | 1 | 2 | 4 | 7 |
| White | 5 | 4 | 3 | 12 |
| Multiple | 0 | 1 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, a key secondary endpoints and safety data of the study.
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Ran from Feb 2022 to primary completion in Apr 2023, 13 months.
Results were first posted in Sep 2024, 1 year 5 months after primary completion.
Of 74 industry-sponsored phase 1 interventional studies under HIV Infections, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 18. This study's 13 months is above that.
Counting every sponsor, half of 165 studies reached it within 19 months; a quarter within 7 and three quarters within 33.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: VH3810109